Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT05107128) looked at a drug called SAGE-718 in people with Huntington's disease. A total of 189 people took part — 94 received a placebo (a dummy treatment with no active ingredient) and 95 received SAGE-718. The trial's main focus was on whether SAGE-718 had any effect on a test called the Symbol Digit Modalities Test (SDMT), which measures thinking speed and attention by asking people to match symbols to numbers within 90 seconds. The trial also measured several other things, including daily independence, motor timing, problem-solving, and how much difficulty people experienced with everyday tasks at home. The reported data shows that on the primary SDMT test, both groups showed a small increase in score from where they started: the placebo group's average score went up by 2.0 points, while the SAGE-718 group's average score went up by 0.8 points (out of a possible 110). For the secondary measures, the reported data shows that on the independence scale, both groups showed a small decline (placebo: −0.8 points; SAGE-718: −1.5 points). On a timed task-switching test (Trail Making Test Part B), both groups were faster than at the start, with the placebo group taking 5.7 seconds less and the SAGE-718 group taking 10.7 seconds less. On a computerised problem-solving test, both groups showed a small improvement in response time (placebo: −4.56 seconds; SAGE-718: −3.85 seconds). On a finger-tapping timing test, the placebo group showed a small improvement (0.710 units) while the SAGE-718 group showed a small decline (−0.157 units). On a self-reported scale of difficulty with everyday tasks at home, the placebo group reported a larger improvement (−4.6 points) compared with the SAGE-718 group (−0.7 points). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Huntington's Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been genetically confirmed to have Huntington's disease, with a specific gene change (CAG repeat of 36 or more) detected by testing.
- Your Huntington's disease is at a mild-to-moderate stage, based on a standard rating scale score (confirm with trial site).
- You do not have the rare childhood-onset form of Huntington's disease.
- You show some level of cognitive (thinking and memory) difficulties, based on a standard memory and thinking test score between 15 and 25.
- You are willing to invite a trusted person aged 18 or over (such as a family member or carer) to take part in the study alongside you, if one is available.
- You are able to walk (using a walking aid like a cane or walker is fine, and occasional wheelchair use is acceptable), and you are able to travel to the study centre regularly throughout the trial.
- You are able to complete a specific thinking and coordination test within 4 minutes at your screening appointment.
Who may not be able to join:
- You have previously taken part in a study of the drug SAGE-718, have ever received gene therapy, have been in a Huntington's disease drug or device trial in the last 6 months, or have been in any other drug or device trial in the last 30 days or longer (note: if you were confirmed to have received a placebo/dummy treatment in a previous trial, you may still be eligible — confirm with trial site).
- You have been diagnosed with another ongoing brain or neurological condition in addition to Huntington's disease, such as Alzheimer's disease, Parkinson's disease, or another form of dementia.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in the SDMT
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.